No Data
Aurisco Pharmaceutical (605116.SH): Plans to spend 60 million yuan to 0.12 billion yuan to repurchase shares.
Gelonghui January 21丨Aurisco Pharmaceutical (605116.SH) announced that the company plans to buy back shares for the conversion of the company's Convertible Bonds. The amount for the share buyback will not be less than 60 million RMB (inclusive) and will not exceed 120 million RMB (inclusive). The maximum price for this share buyback will not exceed 25.00 RMB per share.
Will Weakness in Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Stock Prove Temporary Given Strong Fundamentals?
Aurisco Pharmaceutical (605116.SH): Currently, the company has no pharmaceutical products participating in the national centralized procurement.
On December 20, Gelonghui reported that Aurisco Pharmaceutical (605116.SH) stated on the investor interaction platform that the company currently has no pharmaceutical products participating in the national centralized procurement.
The Recent Pullback Must Have Dismayed Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Insiders Who Own 75% of the Company
Aurisco Pharmaceutical (605116.SH): Currently, there is no collaboration with Novo-Nordisk A/S.
On November 28, Glonghui reported that aurisco pharmaceutical (605116.SH) stated on the investor interaction platform that the company is actively developing the market for the active pharmaceutical ingredient semaglutide, and currently has no collaboration with novo-nordisk a/s.
gf sec: The upstream prices of penicillin and cephalosporins are fluctuating at a high level, while the active pharmaceutical ingredient is finding a bottom and stabilizing.
According to the data from the National Bureau of Statistics, in September 2024, the month-on-month PPI value of chemical drug active pharmaceutical ingredient manufacturing was 97.10, an increase of 2.0 compared to the previous month, and an increase of 1.63 from the average of 95.47 in the first half of 2024. Since the year 2023, when the month-on-month PPI of active pharmaceutical ingredient manufacturing fell below 100 for the whole year, the recent PPI value has been in an increasing state, indicating that the overall price of active pharmaceutical ingredients is in a phase of slight bottoming and recovery.
Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
